Anika Therapeutics to Host Analyst and Investor Day on September 18, 2019
September 04 2019 - 4:05PM
Business Wire
Anika Therapeutics, Inc. (NASDAQ: ANIK), a global, integrated
orthopedics medicines company specializing in therapeutics based on
its proprietary hyaluronic acid ("HA") technology, today announced
that it will host an Analyst and Investor Day on Wednesday,
September 18, 2019 from 9:00 a.m. to 11:30 a.m. ET in Boston,
MA.
Anika’s leadership team will provide updates on its
transformation into a global commercial company and highlights from
the Company’s 5-year strategic plan. Additionally, they will be
joined by the following world leading clinicians to provide
insights about current and potential new treatments in orthopedic
and regenerative medicine.
- Mohit Bhandari, MD, Ph.D., FRCSC, Professor, Orthopaedic
Surgery at McMaster University
- Timothy Deakon, MD, Orthopaedic Surgeon, Director of the
Oakville Sports Injury Clinic
- Kevin Plancher, MD, FAAD, Orthopaedic Surgeon, Plancher
Orthopaedics & Sports Medicine
- Konrad Slynarski, MD, Ph.D., Orthopaedic Surgeon, President of
the Polish Arthroscopy Society
- John Tierney, DO, Orthopaedic Surgeon, President of the Greater
Boston Orthopaedic Center
A live audio webcast of the event may be accessed via the
“Investor Relations” section of Anika’s website at
www.anikatherapeutics.com. An audio archive of the webcast also
will be available on the website.
About Anika Therapeutics, Inc.
Anika Therapeutics, Inc. (NASDAQ: ANIK) is a global,
integrated orthopedic and regenerative medicines company based in
Bedford, Massachusetts. Anika is committed to improving the lives
of patients with degenerative orthopedic diseases and traumatic
conditions with clinically meaningful therapies along the continuum
of care, from palliative pain management to regenerative tissue
repair. The Company has over two decades of global expertise
developing, manufacturing, and commercializing more than 20
products based on its proprietary hyaluronic acid (HA)
technology. Anika's orthopedic medicine portfolio includes
ORTHOVISC®, MONOVISC®, and CINGAL®,
viscosupplements which alleviate pain and restore joint function by
replenishing depleted HA, and HYALOFAST, a solid HA-based
scaffold to aid cartilage repair and regeneration. For more
information about Anika, please visit
www.anikatherapeutics.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20190904005870/en/
For Investor Inquiries: Anika Therapeutics, Inc. Sylvia Cheung,
781-457-9000 Chief Financial Officer
For Media Inquiries: Pure Communications Sonal Vasudev,
917-523-1418 sonal@w2ogroup.com
Anika Therapeutics (NASDAQ:ANIK)
Historical Stock Chart
From Mar 2024 to Apr 2024
Anika Therapeutics (NASDAQ:ANIK)
Historical Stock Chart
From Apr 2023 to Apr 2024